Heterocyclyl substituted arylindenopyrimidines and their use as highly selective adenosine A2A receptor antagonists

Details for Australian Patent Application No. 2010313577 (hide)

Owner Janssen Pharmaceutica NV

Inventors Jackson, Paul F.; Powell, Mark; Shook, Brian Christopher; Wang, Aihua

Agent Shelston IP

Pub. Number AU-A-2010313577

PCT Pub. Number WO2011/053510

Priority 61/255,931 29.10.09 US

Filing date 21 October 2010

Wipo publication date 5 May 2011

International Classifications

C07D 239/70 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 25/16 (2006.01) Drugs for disorders of the nervous system

A61P 25/22 (2006.01) Drugs for disorders of the nervous system

A61P 25/24 (2006.01) Drugs for disorders of the nervous system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 25/30 (2006.01) Drugs for disorders of the nervous system

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

24 May 2012 PCT application entered the National Phase

  PCT publication WO2011/053510 Priority application(s): WO2011/053510

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010313578-Heteroaryl substituted arylindenopyrimidines and their use as highly selective adenosine A2A receptor antagonists

2010313576-Aryl substituted arylindenopyrimidines and their use as highly selective adenosine A2A receptor antagonists